tepoditamab   Click here for help

GtoPdb Ligand ID: 10353

Synonyms: MCLA-117 | MCLA117 | PB9122
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds CLEC12A on myeloid cells and CD3ε on cytotoxic T cells. It is being developed by Merus as a novel therapy for acute myeloid leukemia (AML) [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
MCLA-117 has progressed to Phase 1 clinical evaluation (NCT03038230). Click here to link to ClinicalTrials.gov's full list of MCLA-117 trials.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03038230 MCLA-117 in Acute Myelogenous Leukemia Phase 1 Interventional Merus N.V.